MS_RxCost.jpgIf you subscribe to our monthly RxView Newsletter, then you probably saw the announcement that later in May, annotated data from curated clinical trial results for Multiple Sclerosis (MS) medications will be available in Evidex. Our coverage will include all approved drugs, as well as those in phase II development and above.

Back in June of 2014, the Advera Health team (under our old AdverseEvents banner) wrote our most downloaded report of all time, comparing the safety of MS medications. Given its popularity, I believe that covering the clinical evidence side of MS, including analysis of the drugs’ efficacy, will fill a much needed evidence gap for Evidex subscribers.

To set the stage for the launch of MS coverage, I thought it would be helpful to provide an update to some of the key tables that were in our June 2014 report.

You can download a PDF of the data here, but some main takeaways are listed below:

  • Tecfidera (dimethyl fumarate) had the lowest % of its case reports listing the following serious outcomes: Life-threatening, Hospitalization, Disability, and Death
  • Betaseron (interferon beta-1b) had the highest % of its case reports listing Death as an outcome
  • Avonex (interferon beta-1a) had RORs above 2.0 for “breast cancer” and “rectal cancer” which are not listed in its prescribing information
  • For “heart rate decreased” and “lymphocyte count decreased” Gilenya (fingolimod) had the highest reporting rates by a large margin
  • Rebif (interferon beta-1a) was the only drug analyzed with an ROR above 2 for “suicidal behavior”

Coinciding with the coverage of MS in Evidex, we’ll be providing a written evidence review of Biogen’s soon-to-be-approved pipeline drug, Zinbryta. If you download the updated data tables, you’ll automatically receive a copy of the Zinbryta report as soon as it is published.

Lastly, I wanted to make sure all of our readers were aware of World MS Day taking place on May 25, 2016. World MS Day unites MS organizations globally and raises awareness of multiple sclerosis and those living with MS. Learn more at

I hope you are as excited for our coverage of multiple sclerosis as I am. Feel free to contact us to discuss. 

Andrea Demakas, Product Specialist, Advera Health Analytics, Inc.


Topics: Drug / Indication Information

Andrea Demakas

Written by Andrea Demakas